7 results
Keyword Blinatumomab Remove keyword
Categories
Human Remove Human filter
-
List item
Orphan designation: blinatumomab for: Treatment of acute lymphoblastic leukaemia
Decision date: 24/07/2009, Positiveopinion on orphan designation Blinatumomab for the treatment of acute … Micromet AG, Germany, for blinatumomab for the treatment of acute … information to show that blinatumomab might be of significant benefit … -
List item
Human medicine European public assessment report (EPAR): Blincyto
blinatumomab, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 23/11/2015,
, 
, Revision: 9, Authorised
Blincyto, INN-blinatumomab 30 Churchill Place … cancer medicine Blincyto (blinatumomab) is used in a safe and effective … contains the active substance blinatumomab. More information on Blincyto … -
List item
Human medicine European public assessment report (EPAR): Kymriah
tisagenlecleucel, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 22/08/2018,, , Authorised
cancer medicines clofarabine, blinatumomab or a combination of clofarabine … cancer medicines clofarabine, blinatumomab or a combination of clofarabine … -
List item
Human medicine European public assessment report (EPAR): Spectrila (updated)
asparaginase, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 14/01/2016,, Revision: 3, Authorised
-
List item
Human medicine European public assessment report (EPAR): Yescarta
axicabtagene ciloleucel, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 23/08/2018,, , Revision: 1, Authorised
-
List item
Human medicine European public assessment report (EPAR): Besponsa
inotuzumab ozogamicin, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 28/06/2017,, , Revision: 3, Authorised
-
List item
Orphan designation: inotuzumab ozogamicin for: Treatment of B-cell acute lymphoblastic leukaemia
Decision date: 07/06/2013, Positive